• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by LifeMD Inc.

    4/25/25 4:33:59 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care
    Get the next $LFMD alert in real time by email
    false 0000948320 0000948320 2025-04-24 2025-04-24 0000948320 LFMD:CommonStockParValue0.01PerShareMember 2025-04-24 2025-04-24 0000948320 LFMD:Sec8.875SeriesCumulativePerpetualPreferredStock0.0001PerShareMember 2025-04-24 2025-04-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 24, 2025

     

    LIFEMD, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-39785   76-0238453
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    236 Fifth Avenue, Suite 400
    New York
    , NY 10001
    (Address of principal executive offices, including zip code)

     

    (866) 351-5907
    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   LFMD   The Nasdaq Global Market
    8.875% Series A Cumulative Perpetual Preferred Stock, $0.0001 per share   LFMDP   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01.Changes in Registrant’s Certifying Accountant.

     

    On April 24, 2025 Marcum LLP (“Marcum”), which served as the independent registered public accounting firm of LifeMD, Inc. (the “Company”, “we”, “our”) since 2022, informed the Company that Marcum resigned as the Company’s independent registered public accounting firm. On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum. On April 24, 2025 the Company and with the approval of the Audit Committee of the Company’s Board of Directors, engaged CBIZ CPAs P.C. as the Company’s independent registered public accounting firm.

     

    Marcum’s reports regarding the Company’s financial statements for the years ended December 31, 2024 and December 31, 2023 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

     

    During the years ended December 31, 2024 and 2023, and the interim period from the end of the most recently completed year through April 24, 2025, the date of Marcum’s resignation, there were no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (“Regulation S-K”), and the related instructions thereto, with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in connection with its reports.

     

    During the years ended December 31, 2024 and 2023, and the interim period from the end of the most recently completed year through April 24, 2025, there were no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K except for the following material weaknesses in our internal control over financial reporting related to: (i) our information technology general controls (“ITGCs”), particularly in the areas of user access and change management within our information systems and review of key third-party service provider Systems and Organizational Controls (“SOC”) reports and (ii) business process controls related to Information Produced by the Entity (“IPE”) and system generated IPE and insufficient evidence of formal review and approval procedures of key information utilized in the performance of the control.

     

    The Company provided Marcum with a copy of the foregoing disclosures and requested that Marcum furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of Marcum’s letter furnished pursuant to that request is filed as Exhibit 16.1 to this Current Report on Form 8-K.

     

    During the fiscal years ended December 31, 2024 and 2023 and through April 24, 2025, neither the Company nor anyone on its behalf has consulted with CBIZ CPAs P.C. with respect to either: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ CPAs P.C. concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

     

    Item 9.01.Financial Statements and Exhibits.

     

    Exhibit   Description
         
    16.1   Letter from Marcum LLP, to the Securities and Exchange Commission, dated April 25, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        LIFEMD, INC.
           
    Dated: April 25, 2025 By: /s/ Eric Yecies
          Eric Yecies
          Chief Legal Officer and General Counsel

     

     

     

    Get the next $LFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFMD

    DatePrice TargetRatingAnalyst
    12/10/2024$12.00Buy
    Lake Street
    12/4/2024$7.00Neutral
    Mizuho
    8/23/2024$11.00Buy
    B. Riley Securities
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    11/30/2023$10.00Buy
    Craig Hallum
    7/21/2023$7.00Overweight
    Cantor Fitzgerald
    7/3/2023$9.00Buy
    H.C. Wainwright
    3/10/2022$14.00Buy
    Colliers Securities
    More analyst ratings

    $LFMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by LifeMD Inc.

      10-Q - LifeMD, Inc. (0000948320) (Filer)

      5/6/25 4:45:42 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LifeMD, Inc. (0000948320) (Filer)

      5/6/25 4:10:25 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LifeMD, Inc. (0000948320) (Filer)

      4/28/25 8:47:43 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on LifeMD with a new price target

      Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

      12/10/24 8:29:49 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Mizuho initiated coverage on LifeMD with a new price target

      Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

      12/4/24 7:42:36 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • B. Riley Securities resumed coverage on LifeMD with a new price target

      B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00

      8/23/24 8:12:47 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Financials

    Live finance-specific insights

    See more
    • Medifast Announces First Quarter 2025 Financial Results

      Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we

      4/28/25 4:05:00 PM ET
      $LFMD
      $MED
      Medical/Nursing Services
      Health Care
      Packaged Foods
      Consumer Staples
    • LifeMD to Report First Quarter 2025 Financial Results on May 6

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, a

      4/28/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Acquires Women's Health Provider Optimal Human Health MD to Accelerate Entry into the Women's Health Market

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD ("Optimal"), a nationwide women's health virtual care provider. This strategic acquisition marks LifeMD's official entry into the women's health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness. With women's health historically underserved—particularly in areas such as perimenopause, menopause, and hormonal balance—LifeMD's expansion addresses

      4/28/25 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Leadership Updates

    Live Leadership Updates

    See more
    • LifeMD Set to Join the Russell 3000 Index

      NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

      5/29/24 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Appoints Dr. Calum MacRae to its Board of Directors

      NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

      4/29/24 8:00:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Appoints William J. Febbo to its Board of Directors

      NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec

      6/20/23 8:00:00 AM ET
      $LFMD
      $OPRX
      Medical/Nursing Services
      Health Care
      Business Services
      Consumer Discretionary

    $LFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®

      NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD's virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare® Pharmacy, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support. The collaboration with Novo Nordisk strengthens LifeMD's a

      5/22/25 8:05:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD to Participate in Three Investor Conferences During May

      NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will be holding one-on-one meetings with investors.B. Riley Securities 25th Annual Institutional Investor Conference, May 21-22 at the Ritz-Carlton in Marina Del Rey. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors.Craig-Hallum 22nd Annual Institutional Investor Conference, May 28 at The Depo

      5/12/25 4:05:00 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform. LifeMD's weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single,

      4/29/25 8:05:00 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care

    $LFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      9/12/24 2:10:03 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chairman and CEO Schreiber Justin sold $188,223 worth of shares (25,000 units at $7.53) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      5/5/25 6:02:56 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chairman and CEO Schreiber Justin sold $389,040 worth of shares (50,000 units at $7.78) (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      5/1/25 4:47:52 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Chief Accounting Officer Stan Maria E. was granted 139,375 shares, increasing direct ownership by 205% to 207,500 units (SEC Form 4)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      4/3/25 2:52:40 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

      SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

      11/14/24 10:42:44 AM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

      SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

      2/14/24 3:33:22 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by LifeMD Inc.

      SC 13G - LifeMD, Inc. (0000948320) (Subject)

      10/6/23 5:26:16 PM ET
      $LFMD
      Medical/Nursing Services
      Health Care